Label

Middle East and Africa Smoking Cessation and Nicotine De-Addiction Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 07-Jan-2020 | No of Pages: 80

Price



USD 3995
USD 5795
DM ID :

Publish Date:

07-Jan-2020

Total pages:

80

Middle East and Africa smoking cessation and nicotine de-addiction market is projected to register 27.8% CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:
Middle East and Africa smoking cessation and nicotine de-addiction Market-By Product Type (With Nicotine and Without Nicotine), Treatment Type (Pharmacological, Therapies and Others) Distribution Channel (Online, Offline), End-User (Generation Z, Millennials, Generation X and Silent Generation), By Country (UAE, Saudi Arabia, Egypt, Israel, South Africa and Rest of Middle East and Africa)-Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the Middle East and Africa smoking cessation and nicotine de-addiction market:

• Increasing consumption of e-cigarettes
• Surge in end user for quitting smoking.

Market Players:
The key players of Middle East and Africa smoking cessation and nicotine de-addiction market are:
• Pfizer Inc.
• Dr. Reddy’s Laboratories Ltd
• Glaxosmithkline Plc.
• British American Tobacco
• Cipla Inc.
• Johnson & Johnson Services, Inc

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.